Gene amplification and coamplification in breast cancer: Frequency and prognosis value

Close metadata

Recommended articles:

Comparative immunohistochemistry study of different antibodies clones for detection of breast cancer markers (estrogen receptor, progesterone receptor, HER2/neu, Ki-67). Russian Journal of Archive of Pathology. 2024;(2):14-20

Socio-economic efficiency of the early cancer detection during the medical checkup. Russian Journal of Preventive Medicine. 2024;(1):36-44

Breast biomarkers for the detection of malignancy in benign diseases in women. Russian Journal of Preventive Medicine. 2024;(1):63-66

Methodological approaches to assessing incidence, survival, and mortality rates in breast cancer in the Russian Federation. P.A. Herzen Journal of Oncology. 2024;(1):36-43

Preventive axillary lymphovenous anastomoses simultaneously with lymph node dissection in the treatment of breast cancer for prevention of lymphedema of the upper limb (LYMPHA technique). Pirogov Russian Journal of Surgery. 2024;(2-2):42-47

Fluorescence lymphography for sentinal lymph node biopsy in breast cancer. Pirogov Russian Journal of Surgery. 2024;(2-2):48-54

Domestic system for fluorescent diagnostics in breast cancer: pros and cons. Pirogov Russian Journal of Surgery. 2024;(2-2):55-60

Complications after one-stage and two-stage breast reconstruction depending on the method of reconstruction and risk factors. Plastic Surgery and Aesthetic Medicine. 2024;(2):16-21

Perforator fasciocutaneous flaps in resections for breast cancer. Plastic Surgery and Aesthetic Medicine. 2024;(2):81-86

The impact of artificial intelligence on double reading of mammograms. Russian Journal of Preventive Medicine. 2024;(5):32-37

Numerical impairments in genes or some genome sites - gene amplifications or deletions - are one of the most frequent genetic mutations occurring in breast cancer. Gene amplifications in breast cancer, their frequency, prognostic value, and the possible role of these disorders in the identification of the subtypes of this heterogeneous disease are considered.

Keywords:

gene amplification

breast cancer

FISH analysis

Authors:

Petrov A.V.

State Research Institute of Highly Pure Biopreparations, Federal Biomedical Agency, St. Petersburg, Russia

Pavlenko I.A.

GBU Rostovskoĭ oblasti "Patologoanatomicheskoe biuro", Rostov-na-Donu

Gorelik M.Z.

GBUZ "Primorskoe kraevoe patologoanatomicheskoe biuro", Vladivostok

List of references:

Bombonati A., Sgroi D.C. The molecular pathology of breast cancer progression. J. Pathol. 2011; 223: 307-17.
Kenemans P., Verstraeten R.A., Verheijen R.H.M. Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas. 2004; 49: 34-43.
Lakhani S.R., Ellis I.O., Schnitt S.J., Tan P.H., van de Vijver M.J., eds. WHO Classification of tumours of the breast. IARC: Lyon; 2012.
Jönsson G., Staaf J., Vallon-Christersson J., Ringnér M., Holm K., Hegardt C. et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res. 2010; 12: R42.
Natrajan R., Weigelt B., Mackay A., Geyer F.C., Grigoriadis A., Tan D.S. et al. An integrative genomic and trancriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res. Treat. 2010; 121: 575-89.
Rakha E.A., Reis-Filho J.S., Baehner F., Dabbs D.J., Decker T., Eusebi V. et al. Breast cancer prognostic classification in the molecular era: the role of hostological grade. Breast Cancer Res. 2010; 12: 207.
Möllerström E., Delle U., Danielsson A., Parris T., Olsson B., Karlsoon P. et al. High-resolution genomic profiling to predict 10-year overall survival in mode-negative breast cancer. Cancer Genet. Cytogenet. 2010; 198: 79-89.
Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A. et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-52.
Ross J.S. Multigene classifiers, prognostic factors. And predictors of breast cancer clinical outcome. Adv. Anat. Pathol. 2009; 16: 204-15.
Bizari L., Silva A.E., Tajara E.H. Gene amplification in carcinogenesis. Genet. Mol. Biol. 2006; 29: 1-7.
Ruiz C. Identification and validation of novel amplification target genes in human breast cancer. Basel; 2006.
Al-Kuraya K., Schraml P., Torhorst J., Tapia C., Zaharieva B., Novotny H. et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 2004; 64: 8534-40.
Xu J., Chen Y., Olopade O.I. MYC and breast cancer. Genes & Cancer. 2010; 1: 629-40.
Rummukainen J.K., Salminen T., Lundin J., Kytölä S., Joensuu H., Isola J.J. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod. Pathol. 2001; 14: 1030-5.
Deming S.L., Nass S.J., Dickson R.B., Trock B.J. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br. J. Cancer. 2000; 83: 1688-95.
Rodriguez-Pinilla S.M., Jones R.L., Lambros M.B., Arriola E., Savage K., James M. et al. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J. Clin. Pathol. 2007; 60: 1017-23.
Singhi A.D., Cimino-Mathews A., Jenkins R.B., Lan F., Fink S.R., Nassar H. et al. MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod. Pathol. 2012; 25: 378-87.
Vaziri S.A.J., Tubbs R.R., Darlington G., Casey G. Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. J. Clin. Pathol. Mol. Pathol. 2001; 54: 259-63.
Jirström K., Stendahl M., Rydén L., Kronblad A., Bendahl P.O., Stål O., Landberg G. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res. 2005; 65: 8009-16.
Arnold A., Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J. Clin. Oncol. 2005; 23: 4215-24.
Lundgren K., Holm K., Nordenskjöld B., Borg A., Landberg G. Gene products of chromosome 11q and their association withCCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res. 2008; 10: R1.
Ross J.S., Fletcher J.A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem. Cells. 1998; 16: 413-28.
Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25 (1): 118-45.
Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002; 20: 719-26.
Lamy P.J., Fina F., Bascoul-Mollevi C., Laberenne A.C., Martin P.M., Ouafik L., Jacot W. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res. 2011; 13: 1-12.
Burkhardt L., Grob T.J., Hermann I., Burandt E., Choschzick M., Jänicke F. et al. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res. Treat. 2010; 123: 757-65.
Moelans C.B., de Weger R.A., Monsuur H.N., Vijzelaar R., van Diest P.J. Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod. Pathol. 2010; 23: 1029-39.
Bergamaschi A., Kim Y.H., Wang P., Sørlie T., Hernandez-Boussard T., Lonning P.E. et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes, Chromosomes & Cancer. 2006; 45: 1033-40.
Albertson D. G., Collins C., McCormick F., Gray J.W. Chromosome aberrations in solid tumors. Nat. Genet. 2003; 34: 369-76.
Moelans C.B., de Weger R.A., Monsuur H.N., Maes A.H., van Diest P.J. Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Anal. Cell. Pathol./Cell. Oncol. 2010; 33: 165-73.
Schouten J.P., McElgunn C.J., Waaijer R., Zwijnenburg D., Diepvens F., Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucl. Acids Res. 2002; 30: e57.

Close metadata